|
报告题目：Mycobacterium tuberculosis: Toward a Fast Kill
报告人：ShichuanLun，Senior Research Associate，Johns Hopkins Uuiversity
时间：2014年4月15日上午10:00
|
地点：动医动科楼418室
联系人：索勋
欢迎老师和同学参加！
1. Lun S, Guo H, Onajole OK, Pieroni M, Gunosewoyo H, Chen G, Tipparaju SK, Ammerman NC, Kozikowski AP, Bishai WR. Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nature Communications. 2013 Dec 19; 4:2907. Doi: 10. 1038/ncomms3907.
2. Lun S, Guo H, Adamson J, Cisar JS, Davis TD, Chavadi SS, Warren JD, Quadri LE, Tan DS, Bishai WR. Pharmacokinetic and in vivo Efficacy Studies of the Mycobactin Biosynthesis Inhibitor Salicyl-AMS in Mice. Antimicrob Agents Chemother. 2013 Oct;57(10):5138-40. doi: 10.1128/AAC.00918-13.
3. Bassett IM, Lun S, Bishai WR, Guo H, Kirman JR, Altaf M, O'Toole RF. Detection of inhibitors of phenotypically drug-tolerant Mycobacterium tuberculosis using an in vitro bactericidal screen. J Microbiol. 2013 Jun 25.
4. White EL, Maddox C, Nebane NM, Tower NA, McKellip S, Manuvakhova A, Reddy L, Sosa M, Rasmussen L, Whig K, Ananthan S, Lun S, Bishai W, Weiner WS, Schoenen F, Dutta A, Aubé J. Discovery and Development of Highly Potent Inhibitors of Mycobacterium tuberculosis Growth In Vitro. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. 2011 Apr 15 [updated 2013 Mar 7].
5. Onajole OK, Pieroni M, Tipparaju SK, Lun S, Stec J, Chen G, Gunosewoyo H, Guo H, Ammerman NC, Bishai WR, Kozikowski AP. Preliminary Structure-Activity Relationships and Biological Evaluation of Novel AntitubercularIndolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains. Journal of Medicinal Chemistry. 2013 May 23;56(10):4093-103. doi: 10.1021/jm4003878.
6. Parthasarathy G, Lun S, Guo H, Ammerman NC, Geiman DE, Bishai WR. Rv2190c, an NlpC/P60 Family Protein, Is Required for Full Virulence of Mycobacterium tuberculosis.PLoSONE 2012;7(8):e43429. Epub 2012 Aug 31.
7. Maiga M, Lun S, Guo H, Winglee K, Ammerman NC, Bishai WR. Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550).Journal of Infectious Disease. 2012 June 205(11): 1705-8
8. Lee JH, Ammerman NC, Nolan S, Geiman DE, Lun S, Guo H, Bishai WR. Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis. Nature Communication. 2012 Mar 20;3:753. doi: 10.1038/ncomms1724.
9. Maiga M, Agarwal N, Ammerman NC, Gupta R, Guo H, Maiga MC, Lun S, Bishai WR. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.PLoS ONE. 2012 Feb 7(2): e30749. doi:10.1371/journal.pone.0030749
10. Chopra S, Matsuyama K, Tran T, Malerich JP, Wan B, Franzblau SG, Lun S, Guo H, Maiga MC, Bishai WR and Madrid PB. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.Journal of Antimicrobial Chemotherapy. 2012 Feb (67)2:415-21
